Allarity Therapeutics (ALLR) Competitors $1.49 +0.06 (+4.13%) Closing price 03:59 PM EasternExtended Trading$1.51 +0.02 (+1.48%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. CUE, ANIX, ENGN, UPXI, and COYAShould you buy Allarity Therapeutics stock or one of its competitors? MarketBeat compares Allarity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allarity Therapeutics include Cue Biopharma (CUE), Anixa Biosciences (ANIX), enGene (ENGN), Upexi (UPXI), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry. ALLR vs. CUEALLR vs. ANIXALLR vs. ENGNALLR vs. UPXIALLR vs. COYAHow does Allarity Therapeutics compare to Cue Biopharma?Cue Biopharma (NASDAQ:CUE) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Do insiders and institutionals believe in CUE or ALLR? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 1.8% of Cue Biopharma shares are owned by company insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CUE or ALLR more profitable? Allarity Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-59.65% -98.30% -53.69% Allarity Therapeutics N/A -109.94%-47.27% Does the media favor CUE or ALLR? In the previous week, Cue Biopharma had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 4 mentions for Cue Biopharma and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.00 beat Cue Biopharma's score of 0.66 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, CUE or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$27.47M2.99-$26.60M-$5.58N/AAllarity Therapeutics$320K74.03-$11.23M-$0.72N/A Do analysts prefer CUE or ALLR? Allarity Therapeutics has a consensus price target of $9.75, indicating a potential upside of 554.80%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, CUE or ALLR? Cue Biopharma has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. SummaryAllarity Therapeutics beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.How does Allarity Therapeutics compare to Anixa Biosciences?Anixa Biosciences (NASDAQ:ANIX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Is ANIX or ALLR more profitable? Anixa Biosciences' return on equity of -70.95% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -70.95% -62.53% Allarity Therapeutics N/A -109.94%-47.27% Does the media refer more to ANIX or ALLR? In the previous week, Allarity Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Anixa Biosciences. Allarity Therapeutics' average media sentiment score of 1.00 beat Anixa Biosciences' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ANIX or ALLR? Anixa Biosciences has higher earnings, but lower revenue than Allarity Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K426.31-$10.93M-$0.33N/AAllarity Therapeutics$320K74.03-$11.23M-$0.72N/A Do analysts prefer ANIX or ALLR? Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 218.35%. Allarity Therapeutics has a consensus target price of $9.75, indicating a potential upside of 554.80%. Given Allarity Therapeutics' higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in ANIX or ALLR? 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ANIX or ALLR? Anixa Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. SummaryAnixa Biosciences beats Allarity Therapeutics on 9 of the 15 factors compared between the two stocks.How does Allarity Therapeutics compare to enGene?enGene (NASDAQ:ENGN) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Do insiders & institutionals have more ownership in ENGN or ALLR? 64.2% of enGene shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate ENGN or ALLR? enGene currently has a consensus price target of $12.68, indicating a potential upside of 728.88%. Allarity Therapeutics has a consensus price target of $9.75, indicating a potential upside of 554.80%. Given enGene's stronger consensus rating and higher possible upside, equities research analysts clearly believe enGene is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ENGN or ALLR more profitable? enGene's return on equity of -55.83% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -55.83% -45.74% Allarity Therapeutics N/A -109.94%-47.27% Which has more volatility and risk, ENGN or ALLR? enGene has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Does the media favor ENGN or ALLR? In the previous week, enGene had 7 more articles in the media than Allarity Therapeutics. MarketBeat recorded 10 mentions for enGene and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.00 beat enGene's score of -0.04 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ENGN or ALLR? Allarity Therapeutics has higher revenue and earnings than enGene. Allarity Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$117.30M-$2.25N/AAllarity Therapeutics$320K74.03-$11.23M-$0.72N/A SummaryenGene beats Allarity Therapeutics on 9 of the 14 factors compared between the two stocks.How does Allarity Therapeutics compare to Upexi?Upexi (NASDAQ:UPXI) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Is UPXI or ALLR more profitable? Allarity Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Upexi-874.00% -66.70% -19.56% Allarity Therapeutics N/A -109.94%-47.27% Does the media favor UPXI or ALLR? In the previous week, Upexi had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 6 mentions for Upexi and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.00 beat Upexi's score of -0.51 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend UPXI or ALLR? Upexi presently has a consensus target price of $8.33, indicating a potential upside of 545.99%. Allarity Therapeutics has a consensus target price of $9.75, indicating a potential upside of 554.80%. Given Allarity Therapeutics' higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals have more ownership in UPXI or ALLR? 5.7% of Upexi shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, UPXI or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than Upexi. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$15.81M5.73-$13.68M-$3.23N/AAllarity Therapeutics$320K74.03-$11.23M-$0.72N/A Which has more risk & volatility, UPXI or ALLR? Upexi has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. SummaryUpexi and Allarity Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.How does Allarity Therapeutics compare to Coya Therapeutics?Allarity Therapeutics (NASDAQ:ALLR) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has more volatility & risk, ALLR or COYA? Allarity Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Is ALLR or COYA more profitable? Allarity Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -109.94% -47.27% Coya Therapeutics -266.10%-55.86%-48.86% Does the media prefer ALLR or COYA? In the previous week, Coya Therapeutics had 4 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for Coya Therapeutics and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 1.00 beat Coya Therapeutics' score of 0.45 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ALLR or COYA? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 0.0% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, ALLR or COYA? Allarity Therapeutics has higher earnings, but lower revenue than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity Therapeutics$320K74.03-$11.23M-$0.72N/ACoya Therapeutics$7.95M13.49-$21.23M-$1.15N/A Do analysts recommend ALLR or COYA? Allarity Therapeutics presently has a consensus target price of $9.75, suggesting a potential upside of 554.80%. Coya Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 250.11%. Given Allarity Therapeutics' higher possible upside, equities analysts plainly believe Allarity Therapeutics is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryAllarity Therapeutics and Coya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition ExportMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.75M$3.25B$6.25B$12.23BDividend YieldN/A2.34%2.80%5.27%P/E Ratio-2.0718.5220.7925.04Price / Sales74.03270.32531.2172.18Price / CashN/A124.5843.0954.25Price / Book3.466.609.816.83Net Income-$11.23M$24.18M$3.55B$335.69M7 Day Performance-2.04%-3.56%-2.07%-2.03%1 Month Performance21.06%-7.86%-3.90%-1.90%1 Year Performance39.16%51.80%29.39%27.36% Allarity Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics2.7002 of 5 stars$1.49+4.1%$9.75+554.8%+37.5%$22.75M$320KN/A10Positive NewsEarnings ReportCUECue Biopharma0.9583 of 5 stars$29.26-6.6%N/A-96.7%$101.96M$27.47MN/A60Earnings ReportAnalyst UpgradeANIXAnixa Biosciences1.8451 of 5 stars$2.95-2.6%$8.50+188.1%+4.2%$101.59M$210KN/A5ENGNenGene3.4158 of 5 stars$1.44-3.4%$13.41+831.2%-54.5%$99.81MN/AN/A31News CoverageUPXIUpexi2.2378 of 5 stars$1.35-8.2%$8.33+517.3%-87.0%$98.37M$24.74MN/A130Earnings ReportGap Down Related Companies and Tools Related Companies Cue Biopharma Alternatives Anixa Biosciences Alternatives enGene Alternatives Upexi Alternatives Coya Therapeutics Alternatives Promis Neurosciences Alternatives Athira Pharma Alternatives NRx Pharmaceuticals Alternatives aTyr Pharma Alternatives Forum Markets Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
